- Molecular NameNabilone
- Synonymnabilone
- Weight372.549
- Drugbank_IDDB00486
- ACS_NO51022-71-0
- Show 3D model
- LogP (experiment)6.909
- LogP (predicted, AB/LogP v2.0)7.65
- pkaN/A
- LogD (pH=7, predicted)7.65
- Solubility (experiment)0.0005 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-5.99
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors1
- No.of HBond Acceptors3
- No.of Rotatable Bonds6
- TPSA46.53
- StatusFDA approved
- AdministrationN/A
- PharmacologyA synthetic cannabinoid with therapeutic use as an antiemetic and as an adjunct analgesic for neuropathic pain. It is a synthetic cannabinoid, which mimics the main ingredient of marijuana (THC).
- Absorption_valueN/A
- Absorption (description)Rapidly absorbed from the gastrointestinal tract following oral administration.
- Caco_2N/A
- Bioavailability20.0
- Protein bindingN/A
- Volume of distribution (VD)12.5 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic. Two metabolic pathways have been suggested. The major pathway probably involves the direct oxidation of Nabilone to produce hydroxylic and carboxylic analogues. These compounds are thought to account for the remaining plasma radioactivity when carbinol metabolites have been extracted.
- Half life2 h, with metabolites around 35 h.
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overdose include difficulty in breathing, hallucinations, mental changes (severe), nervousness or anxiety (severe).
- LD50 (rat)N/A
- LD50 (mouse)N/A